10 patients with presumptive diagnosis of dysautonomia with chronic nausea, vomiting and food intolerance

Dysautonomia

The celiac ganglion block will be performed under CT guidance and with the patent under moderate sedation. With the patient prone the back will be prepped and draped sterility. Under CT guidance two 22 gauge needles will be placed with the tips on either side of the celiac artery. This is the location of the celiac ganglia. Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based. Then patient will be observed for 1-2 hours post procedure and then discharged to home

Celiac ganglion block

Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based.

Liposomal bupivacaine

Johns Hopkins University

Temporary Celiac Ganglion Block as a Test Before Celiac Ganglion Resection for Dysautonomia-Related Bowel Dysmotility

Prospective Single-Arm Pilot Study for CT-Guided, Temporary Celiac Ganglion Block as a Test Before Celiac Ganglion Resection for Dysautonomia-Related Bowel Dysmotility

Over the 2 days post Celiac Ganglion block, the investigators will monitor the patient (outpatient) for amount of solid food intake (grams) per day.

Patients with GI involvement of dysautonomia have abdominal pain which is worse with solid food intake. The patient's ability to take solid food without pain will be evaluated on scale 1-10 with 10 being worse pain.

The frequency of nausea/vomiting will be tabulated.

Patients with GI dysautonomia have chronic abdominal pain and take almost daily analgesic medication. The investigators shall evaluate the use of analgesic medication for the duration of the Celiac Ganglion block.

10 patients with chronic GI dysmotility, chronic nausea/vomiting and feeding intolerance requiring G-J feeding and considered for Celiac Ganglion resection

Since this is a single arm study, no masking will be performed

flecainide x 6 months, then crossover to sotalol x 6 months

sotalol x 6 months, then crossover to flecainide x 6 months

Atrial Fibrillation

flecainide up to 150mg twice daily for the control of atrial fibrillation

Flecainide

sotalol up to 120mg twice daily for the control of atrial fibrillation

Sotalol

Jesse Brown VA Medical Center

Rush University Medical Center

University of Illinois at Chicago

Advocate Christ Medical Center

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs

Subjects will be monitored with the Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) system to assess AF burden. The device will be programmed to optimize the memory for storing AF episode..

Quality of life assessment: Patients will be asked to fill out the AFEQT quality of life questionnaire baseline (study randomization), two, four, six, eight, ten, and 12 months (completion of the study). The questionnaire at the end of the 6rd month will be administered just prior to stopping the first study drug. The validated questionnaire is comprised of 20 questions about AF symptoms with answers given on a Likert scale. The questionnaire will be provided to the patients in paper format either in person or by mail, as applicable. A follow-up phone call will be made to each patient to ensure that the questionnaire is completed and returned.

Dawood Darbar, MD

Professor of Medicine

Medtronic

Autologous Stem Cell Transplant will be performed on eligible patients

Allogeneic Stem Cell Transplant will be performed on eligible patients

Autologous Stem Cell Transplant will be performed on eligible patients
Autologous Stem Cell Transplant: Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning

Autologous Stem Cell Transplant

Allogeneic Stem Cell Transplant will be performed on eligible patients
Allogeneic Stem Cell Transplant: Allogeneic Stem Cell Transplant will be performed after conditioning

Allogeneic Stem Cell Transplant

Total

Sex: Female, Male

Region of Enrollment

Survival

Overall Study

Dr Richard Burt

Vasculitis

Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning

Allogeneic Stem Cell Transplant will be performed after conditioning

Cyclophosphamide

A rabbit polyclonal antibody to lymphocyte

ATG (rabbit)

G-CSF

Humanized monoclonal antibody against CD52 antigen

Campath-1h

Fludarabine

Tacrolimus

Mesna is a drug used to protect the bladder from the effects of the chemotherapy drugs

Mesna

Northwestern University, Feinberg School of Medicine

Hematopoietic Stem Cell Support in Vasculitis

High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome

vasculitis/nudności

Temporary Celiac Ganglion Block as a Test Before Celiac Ganglion Resection for Dysautonomia-Related Bowel Dysmotility

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

Hematopoietic Stem Cell Support in Vasculitis

Najbardziej kompletna baza danych ziół leczniczych poparta naukowo